Stem Cells Fight Sickle Cell Anemia in New Clinical Trials New Gene Therapy Treatment Could Potentially Cure Sickle Cell Anemia
A new gene therapy treatment could potentially cure sickle cell anemia, a lifelong blood disorder that affects millions of people worldwide. The treatment, which is currently undergoing clinical trials, would harvest a patient’s own stem cells and add to them a corrected gene that makes non-sickle hemoglobin.
If successful, the gene therapy could significantly improve the quality of life for those affected by sickle cell anemia, which can lead to frequent pain, organ damage and even stroke.
Sickle cell anemia is a genetic blood disorder that affects millions of people worldwide. While the disease is most commonly found in people of color, it can also affect people of Caucasian descent.
The disease has a high prevalence in certain parts of the world, with up to 40% of the population in the Mediterranean region suffering from sickle cell anemia. In the U.S., about 100,000 people are estimated to have sickle cell anemia, affecting about 1 in every 365 African American births and 1 in every 16,000 Hispanic American births.
The symptoms of sickle cell anemia can vary significantly from person to person, but they often include frequent episodes of pain that significantly impact daily life. Other symptoms include swelling of the hands and feet, frequent infections, vision problems and delayed growth or puberty.
Early diagnosis and treatment of sickle cell anemia can help to reduce the risk of long-term complications, such as stroke and organ damage. However, treatment options for the disease remain limited and many people with sickle cell anemia live with limited resources. The recent advances in gene therapy are offering new hope for people affected by sickle cell anemia.
Gene therapy is a type of treatment that involves taking bone marrow or other stem cells from a patient and genetically engineering them to correct a disease. A newer form of gene therapy, known as CRISPR gene therapy, has shown promise in treating sickle cell anemia.
CRISPR gene therapy involves taking CRISPR protein, a powerful gene-editing tool, and using it to correct a specific gene defect in the patient’s blood-forming cells. While CRISPR gene therapy has not yet been tested in a clinical trial, early results are promising.
In a small study, patients with sickle cell anemia who received CRISPR gene therapy experienced significant improvements in their pain levels and quality of life. If successful, CRISPR gene therapy could offer a long-term cure for sickle cell anemia and significantly improve the lives of those affected by the disease.
